Synchronous Primary Endometrial and Ovarian Cancers: Pathogenesis, Treatment and Prognosis by Androutsopoulos G & Decavalas G
International Journal of Clinical Therapeutics and Diagnosis, 2014 © 1
Androutsopoulos G, Decavalas G (2014) Synchronous Primary Endometrial and Ovarian Cancers: Pathogenesis, Treatment and Prognosis. Int J Clin Ther Diagn. 2(2), 1-2.
International Journal of Clinical Therapeutics and Diagnosis (IJCTD)
ISSN 2332-2926
Synchronous Primary Endometrial and Ovarian Cancers: Pathogenesis, Treatment and Prognosis
           
          Editorial
Androutsopoulos G1*,  Decavalas G1
1 Department of  Obstetrics and Gynecology, University of  Patras, Medical School, Rion, Greece.
*Corresponding Author: 
Georgios Androutsopoulos MD, 
Lecturer, Department of  Obstetrics and Gynecology, 
University of  Patras, Medical School, 
Rion 26504, Greece.
Tel: +306974088092
E-mail: androutsopoulos@upatras.gr
Received: August 02, 2014
Published: August 27, 2014
Citation: Androutsopoulos G, Decavalas G (2014) Synchronous Pri-
mary Endometrial and Ovarian Cancers: Pathogenesis, Treatment 
and Prognosis. Int J Clin Ther Diagn. 2(2), 1-2. doi: http://dx.doi.
org/10.19070/2332-2926-140005e
Copyright: Georgios Androutsopoulos © 2014. This is an open-access 
article distributed under the terms of  the Creative Commons Attribution 
License, which permits unrestricted use, distribution and reproduction in 
any medium, provided the original author and source are credited. 
Synchronous primary cancers are relatively uncommon in gen-
eral population.[1] Only 0.5-1.7% of  women with gynecological 
malignancies, have synchronous primary cancers of  the female 
genital tract.[2-6] Among them, the most common combination 
is synchronous primary endometrial and ovarian cancers.[2,3,5]
The pathogenesis of  synchronous primary endometrial and ovar-
ian cancers, remains unclear[5,7] The theory of  the secondary 
Müllerian system has been proposed to explain the development 
of  multiple primary cancers of  the female genital tract.[5-9] Ac-
cording to this theory, epithelia of  the female genital tract simul-
taneously respond to a carcinogenic stimulus.[7,8]
Perhaps those patients have a more fragile genome and prior ge-
netic damage may predispose to the development of  synchronous 
primary cancers of  the female genital tract.[7,10-14] Thus, em-
bryologic, hormonal or other phenomena may be associated with 
the development of  synchronous primary endometrial and ovar-
ian cancers.[5-10,12]
Systematic surgical staging is the treatment of  choice, for most 
patients with synchronous primary endometrial and ovarian can-
cers[2,3,5,15-21] More specifically, systematic surgical staging in 
those patients includes: total abdominal hysterectomy with bilat-
eral salpingo-oophorectomy, total omentectomy, appendectomy, 
pelvic and para-aortic lymphadenectomy, complete resection of  
all disease, biopsy of  any suspected lesion and pelvic washings.
[1,2,5,15-19,21-23]
It is obvious that systematic surgical staging allows a more clear 
decision for stage related postoperative adjuvant treatment.
[1,17,18] Appropriate surgical staging facilitates targeted therapy 
that minimize the morbidity of  overtreatment (radiation injury, 
chemotherapy toxicity), the effects of  undertreatment (recurrent 
disease, increased mortality) and maximize survival.[24]
Pelvic and para-aortic lymphadenectomy has diagnostic, thera-
peutic and prognostic value.[1,22,23] It defines accurately the 
extent of  disease and determines the prognosis of  patients.[1] 
Undoubtedly, it is necessary for the identification of  patients with 
stage III disease. [22,23] The extension of  pelvic and para-aortic 
lymphadenectomy (more than 14 lymph nodes) is an independent 
risk factor for postoperative complications.[17,18,25-27] Espe-
cially in elderly patients and in patients with relevant comorbidi-
ties (obesity, diabetes, coronary artery disease), morbidity must be 
carefully weighed against any survival advantage.[24,28,29]
The significance of  postoperative adjuvant treatment in patients 
with synchronous primary endometrial and ovarian cancers, re-
mains controversial and needs further investigation.[16,20,30] In 
most cases, postoperative adjuvant treatment should be individu-
alized according to the risk of  relapse of  each primary cancer.
[30,31] Moreover, the treatment of  one primary cancer does not 
compromise the treatment of  the other primary cancer.[32]
Especially in patients with unfavorable histologic types, high 
grade and/or advanced stage disease, required postoperative ad-
juvant treatment tailored to both tumors.[3,5,15,17-21,30,32-36] 
More specifically, postoperative adjuvant treatment in those pa-
tients includes: radiotherapy and/or chemotherapy.[1,21,30,36]
Postoperative adjuvant radiotherapy includes: external pelvic ra-
diotherapy and/or brachytherapy. It is the appropriate treatment 
for high risk primary endometrial cancer.[1,17,18]
Postoperative adjuvant chemotherapy is the appropriate treatment 
for advanced stage primary endometrial and ovarian cancers.[31] 
The most active chemotherapeutic agents for those patients, are: 
taxanes, anthracyclines and platinum compounds.[20,21]
Prognostic factors for synchronous primary endometrial and ovar-
ian cancers are: age, grade of  endometrial cancer, stage of  ovarian 
cancer and adjuvant treatment.[35,37,38] Patients with synchro-
nous primary endometrial and ovarian cancers have 5-year overall 
survival 85.9% and 10 year overall survival 80.3%.[16] However, 
patients with synchronous primary endometrial and ovarian can-
cers endometrioid type have a better overall survival compared 
with patients with non-endometrioid or mixed histologic types.
[39] Moreover, patients with synchronous primary endometrial 
and ovarian cancers have better overall survival compared with 
patients with single primary ovarian cancer.[30,32,35,39]
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The reason for the better overall survival of  patients with syn-
chronous primary endometrial and ovarian cancers, is not intui-
tively obvious.[16] Perhaps favorable prognosis related with the 
detection of  patients at early stage and low grade disease.[3,5,11-
13,15-34,40]
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